Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mi2 Holdings
Houston, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Mi2 Holdings is developing NanoMark, a next-generation MRI imaging agent enabling direct, highly specific visualization of cancer, intended to improve early and late-stage cancer detection. Current results are preclinical, with proven and patented science developed in collaboration with leading US research institutions, but no clinical trial data is published yet.[1]
- Therapeutic areas
- Oncology
- Modalities
- Imaging agentNanoparticle
- Industry
- Medical Imaging
02
Partnerships
Collaboration with US research institutionsLicense partnership with Kuva Labs (for solid tumor imaging technology)
Beyond the preview
Go deeper on Mi2 Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mi2 Holdings.